Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma.
about
Bladder Preservation for Muscle Invasive Bladder CancerSaudi Oncology Society and Saudi Urology Association combined clinical management guidelines for urothelial cell carcinoma of the urinary bladderThe impact of hypoxia and its modification of the outcome of radiotherapyCurrent perspectives in bladder cancer managementBladder Sparing Approaches for Muscle-Invasive Bladder CancersIdentification of gene expression signature modulated by nicotinamide in a mouse bladder cancer modelPhase I Clinical Trial of Everolimus Combined with Trimodality Therapy in Patients with Muscle-Invasive Bladder Cancer.Expression of hypoxia-inducible factor-1α predicts benefit from hypoxia modification in invasive bladder cancerLong-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.Nicotinamide inhibits vasculogenic mimicry, an alternative vascularization pathway observed in highly aggressive melanomaRadiotherapy in muscle-invasive bladder cancer: the latest research progress and clinical applicationSelective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder.Modulation of the tumor vasculature and oxygenation to improve therapyEnhanced stability of microRNA expression facilitates classification of FFPE tumour samples exhibiting near total mRNA degradation.Urothelial carcinoma management in elderly or unfit patients.New paradigms and future challenges in radiation oncology: an update of biological targets and technology.Expression of miR-210 in relation to other measures of hypoxia and prediction of benefit from hypoxia modification in patients with bladder cancer.A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer.Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial.SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016).Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer.Current management of muscle-invasive bladder cancer.Carbogen gas and radiotherapy outcomes in prostate cancer.Selective organ preservation for the treatment of muscle-invasive transitional cell carcinoma of the bladder: a review of current and future perspectives.Molecular imaging of hypoxia in non-small-cell lung cancer.Realistic biological approaches for improving thermoradiotherapy.Incidental Dose to Pelvic Nodes in Bladder-Only Radiotherapy: Is It Clinically Relevant?Tumor hypoxia and reoxygenation: the yin and yang for radiotherapy.Imatinib radiosensitizes bladder cancer by targeting homologous recombination.Pre-treatment lymphocytopaenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer.Perfluorocarbon emulsions radiosensitise brain tumors in carbogen breathing mice with orthotopic GL261 gliomas.Comparison of adaptive radiotherapy techniques for the treatment of bladder cancer.Hypoxia Marker GLUT-1 (Glucose Transporter 1) is an Independent Prognostic Factor for Survival in Bladder Cancer Patients Treated with Radical Cystectomy.The anti-PD-1 era - an opportunity to enhance radiotherapy for patients with bladder cancer.Radiosensitisation in vivo by histone deacetylase inhibition with no increase in early normal tissue radiation toxicity.Bladder cancer and the National Cancer Data Base: New insight or misinformation?The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004).Targeting tumour hypoxia to improve outcome of stereotactic radiotherapy.Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for urothelial cell carcinoma of the urinary bladder 2017.Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer.
P2860
Q26744750-4B6B2CE3-95E9-409E-8515-2D3A9B0A0E21Q26747775-AA49D692-8B66-4EDB-BA8A-A05C57E5A4BFQ26779537-240E8B7C-0147-4367-8C81-8D1B3803ADD1Q26824914-0A6F820F-1B91-4074-BE96-9C4920C7B91CQ28072814-843A0BE0-ADFC-4F83-A5CC-32522C96DFD0Q28477425-AB54B741-3DC4-451C-A9BA-1F73CA3E17AEQ33614537-087D542C-68B8-4944-AC5B-EB1C530643F2Q33994365-D1007892-9B3F-4F20-877A-60A6C673B011Q34551018-90AD1CD1-444A-4597-A5E9-56D903B26115Q34603154-D419FCE0-A766-43CF-9AD3-F51A922FB8FCQ35402431-A9B4D57C-5822-4439-A869-7262E008506AQ35603639-CB86B536-B284-4BC2-BEF9-B8040197DEFEQ35920685-28C3DFB1-E804-4CEE-AD72-E7E942861B4AQ36166783-E8CCE2BD-E2FE-4A77-9944-7882DE79D30FQ37030514-DB63114D-7700-4E0C-8C55-C996F8EB4A45Q37160539-0800B5B6-A361-4294-8CD2-11387B4110B9Q37203114-6373F16C-641E-4C93-B46C-93E4AD982D35Q37231848-C7B6D991-0B34-4736-A2B3-6DD3BE32D28EQ37453556-6E7D7A2C-5B25-40A9-89C6-AE58D738E8F3Q37475193-C058454D-39FE-4EB5-9982-78FF9F857812Q37671964-0F3367E5-E749-43B4-802F-7726C6286A08Q37962658-4B2F4DE1-2B9D-4E0E-AB5F-7C7E1108AA8FQ38078362-FBBC5D09-BECD-43C7-B9F9-6F476EB578A4Q38255032-685C0204-2D5E-4DCE-B5F8-C4F6251C6E54Q38363234-7DF81920-2FBB-435F-A153-76FA0AE7958AQ38648236-70B90828-F137-4E1E-8040-549608621F75Q38974743-B9920156-131D-49E2-BF4A-0756B90C8E22Q39061401-CC92F4EE-A715-488C-8C99-959BAE3B90E5Q39213528-CDF56FDA-1B92-4528-802C-2BC202B13C46Q41116973-6C6C3E8C-C55F-4FE6-90F2-57B52AA9EFE3Q41617947-3E544746-4B45-41DA-9309-3D1D9B960392Q42287176-2E601C5F-09CA-43FB-B9A4-5E8B009A4C9BQ42488078-2BCC01A0-39EE-455A-9E73-51F90A9B305AQ47580489-7B59496B-363D-4F6D-AC6F-014F64D093C4Q47908872-C26A6262-C9BD-4A68-AC47-61428EF10C53Q48234885-838C76DC-4C1B-434C-A65D-44E54F32EC0DQ51167495-56FFF21A-6923-4425-9963-19BD06E70135Q51598914-AE27BE08-AB85-4BA5-B902-BDC0E0C7FB49Q55013973-57D01B2D-55AB-410A-B8B3-0E800DBF9E2EQ55398136-DA04F29A-20BD-4B15-BF8F-3256BBDF656A
P2860
Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma.
@en
Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma.
@nl
type
label
Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma.
@en
Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma.
@nl
prefLabel
Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma.
@en
Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma.
@nl
P2093
P356
P1476
Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma.
@en
P2093
Ana M Rojas
Michele I Saunders
Peter J Hoskin
Søren M Bentzen
P304
P356
10.1200/JCO.2010.28.4950
P407
P577
2010-10-18T00:00:00Z